| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Chao-Chi Ho;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; CHAO-CHI HO; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:40Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.; Xiao F.; Shih J.-Y.; CHAO-CHI HO; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M.; Yang W.-C.;Xiao F.;Shih J.-Y.;Chao-Chi Ho;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M. |
| 臺大學術典藏 |
2020-08-12T02:50:39Z |
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
|
Liao W.-Y.;Chao-Chi Ho;Tsai T.-H.;Chen K.-Y.;Shih J.-Y.;Yu C.-J.; Liao W.-Y.; CHAO-CHI HO; Tsai T.-H.; Chen K.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:39Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Shih J.-Y.; Ko J.-C.; CHAO-CHI HO; Liang S.-K.;Lee M.-R.;Liao W.-Y.;Chao-Chi Ho;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Lee M.-R.; Liao W.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:39Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
|
Lee J.-H.; Lin C.-C.; Liao W.-Y.; CHAO-CHI HO; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.; Wu T.-H.; Hsiue E.H.-C.; Wu T.-H.;Hsiue E.H.-C.;Lee J.-H.;Lin C.-C.;Liao W.-Y.;Chao-Chi Ho;Shih J.-Y.;Yu C.-J.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:38Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
Shih J.-Y.; Hsu C.-L.; Lin C.-K.; Liao W.-Y.; CHAO-CHI HO; Yu K.-L.;Tsai T.-H.;Chao-Chi Ho;Liao W.-Y.;Lin C.-K.;Hsu C.-L.;Shih J.-Y.; Yu K.-L.; Tsai T.-H. |
| 臺大學術典藏 |
2020-08-12T02:50:37Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Hsu C.-L.; CHAO-CHI HO; Liao W.-Y.; Chen J.-S.; Lin Y.-T.; Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Chao-Chi Ho;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Wu C.-T.; Chang Y.-L.; Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-24T08:58:41Z |
Unfavourable environment limits social conflict in Yuhina brunneiceps
|
Shen, S.-F .; Vehrencamp, S.L .; Johnstone, R.A .; Chen, H.-C .; Chan, S.-F .; Liao, W.-Y .; Lin, K.-Y .; Yuan, H.-W.; SHENG-FENG SHEN |
| 臺大學術典藏 |
2020-07-21T06:46:34Z |
TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer
|
CHAO-CHI HO; Liao W.-Y.; Wang C.-Y.; Lu Y.-H.; Huang H.-Y.; Chen H.-Y.; Chan W.-K.; Chen H.-W.; Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:31Z |
Risk Factors of Pneumothorax after Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Lung Lesions
|
Yu C.-J.; Huang C.-T.; Ruan S.-Y.; Liao W.-Y.; Kuo Y.-W.; Lin C.-Y.; Tsai Y.-J.; CHAO-CHI HO |
| 臺大學術典藏 |
2020-07-21T06:46:31Z |
Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: How many specimens are necessary?
|
Yang P.-C.; Yu C.-J.; CHAO-CHI HO; Wu P.-C.; Liao W.-Y.; Tsai Y.-J.; Huang C.-T. |
| 臺大學術典藏 |
2020-07-21T06:46:29Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Shih J.-Y.; Ruan S.-Y.; Wang J.-Y.; Tsai T.-H.; Yang C.-Y.; CHAO-CHI HO; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Yang P.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:29Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Chen K.-Y.; Wu M.; Shih J.-Y.; Chen J.-H.; Liao W.-Y.; CHAO-CHI HO; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:27Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; CHAO-CHI HO; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:27Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Yu C.-J.; Lee C.-H.; Yang P.-C.; Lee Y.-C.; Chen H.-Y.; Liao W.-Y.; CHAO-CHI HO; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:26Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:25Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu K.-L.; CHAO-CHI HO; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:25Z |
Prospective evaluation of procalcitonin, soluble triggering receptor expressed on myeloid cells-1 and c-reactive protein in febrile patients with autoimmune diseases
|
Lin C.-H.; Hsieh S.-C.; Keng L.-T.; Lee H.-S.; Chang H.-T.; Liao W.-Y.; CHAO-CHI HO; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:22Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yang J.C.H.; Yu C.-J.; Lin C.-C.; Yao Z.-H.; Lin Z.-Z.; Chen J.-S.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:22Z |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
CHAO-CHI HO; Liao W.-Y.; Lin C.-A.; Shih J.-Y.; Yu C.-J.; Chih-Hsin Yang J. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:20Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M.; Liao W.-Y.; Chen K.-Y.; Tseng H.-M.; Chen Y.-F.; CHAO-CHI HO; Shih J.-Y.; Xiao F.; Yang W.-C. |
